Hyloris Developmentsen Sa Total Liabilities

Latest as of June 2025: €8.16 Million EUR ≈ $9.54 Million USD

Hyloris Developmentsen Sa total liabilities. Based on the latest financial reports, Hyloris Developmentsen Sa (HYL) has total liabilities worth €8.16 Million EUR (≈ $9.54 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Hyloris Developmentsen Sa to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Hyloris Developmentsen Sa (2016–2024)

Total liabilities of Hyloris Developmentsen Sa from 2016 to 2024. This chart illustrates how Hyloris Developmentsen Sa's total liabilities have evolved over time, based on quarterly financial data.

Hyloris Developmentsen Sa Competitors by Total Liabilities

The table below lists competitors of Hyloris Developmentsen Sa ranked by their total liabilities.

Company Country Total Liabilities
Trio-Tech International
NYSE MKT:TRT
USA $13.99 Million
Caisse Regionale De Credit Agricole Mutuel Sud Rhone Alpes
PA:CRSU
France €24.15 Billion
Silk Logistics Holdings Ltd
AU:SLH
Australia AU$479.39 Million
BINEX Co. Ltd
KQ:053030
Korea ₩117.14 Billion
Mitrabara Adiperdana PT
JK:MBAP
Indonesia Rp54.08 Million
LiveWire Group Inc.
NYSE:LVWR
USA $99.31 Million
Nykode Therapeutics ASA
OL:NYKD
Norway Nkr5.73 Million
Pioneer Floating Rate Trust
NYSE:PHD
USA $66.83 Million

Liability Composition Analysis (2016–2024)

This chart breaks down Hyloris Developmentsen Sa's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Hyloris Developmentsen Sa total assets.

Liquidity & Leverage Metrics

Hyloris Developmentsen Sa Total Liabilities Ratios Explained

Hyloris Developmentsen Sa total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 3.82 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.28 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.22 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Hyloris Developmentsen Sa's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Hyloris Developmentsen Sa (2016–2024)

The table below shows the annual total liabilities of Hyloris Developmentsen Sa from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 €9.19 Million
≈ $10.75 Million
+6.73%
2023-12-31 €8.61 Million
≈ $10.07 Million
+26.29%
2022-12-31 €6.82 Million
≈ $7.97 Million
-55.69%
2021-12-31 €15.39 Million
≈ $17.99 Million
+52.01%
2020-12-31 €10.12 Million
≈ $11.83 Million
-37.40%
2019-12-31 €16.17 Million
≈ $18.91 Million
+30.31%
2018-12-31 €12.41 Million
≈ $14.51 Million
+43.45%
2017-12-31 €8.65 Million
≈ $10.11 Million
+144.86%
2016-12-31 €3.53 Million
≈ $4.13 Million
--

About Hyloris Developmentsen Sa

BR:HYL Belgium Biotechnology
Market Cap
$123.41 Million
€105.56 Million EUR
Market Cap Rank
#18200 Global
#81 in Belgium
Share Price
€3.77
Change (1 day)
-0.26%
52-Week Range
€3.65 - €8.10
All Time High
€18.90
About

Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the h… Read more